IRIS
BATTISTA, TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.052
NA - Nord America 1.853
EU - Europa 1.846
SA - Sud America 376
AF - Africa 82
OC - Oceania 4
Totale 7.213
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.763
SG - Singapore 1.304
RU - Federazione Russa 875
CN - Cina 742
DE - Germania 546
VN - Vietnam 408
BR - Brasile 312
HK - Hong Kong 173
IN - India 126
IT - Italia 112
KR - Corea 95
FI - Finlandia 81
FR - Francia 68
JP - Giappone 48
CA - Canada 43
GB - Regno Unito 43
BD - Bangladesh 40
AR - Argentina 30
CI - Costa d'Avorio 26
ZA - Sudafrica 24
MX - Messico 23
NL - Olanda 18
IQ - Iraq 17
PK - Pakistan 17
UA - Ucraina 16
PL - Polonia 15
ES - Italia 14
EC - Ecuador 12
ID - Indonesia 12
AT - Austria 10
PH - Filippine 10
MA - Marocco 8
TH - Thailandia 8
KE - Kenya 7
SE - Svezia 7
TR - Turchia 7
EG - Egitto 6
IE - Irlanda 6
JO - Giordania 6
LT - Lituania 6
PY - Paraguay 6
TW - Taiwan 6
IL - Israele 5
JM - Giamaica 5
RS - Serbia 5
SA - Arabia Saudita 5
CL - Cile 4
CO - Colombia 4
TN - Tunisia 4
VE - Venezuela 4
AZ - Azerbaigian 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
MY - Malesia 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BE - Belgio 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
HN - Honduras 2
HR - Croazia 2
KH - Cambogia 2
LB - Libano 2
OM - Oman 2
PE - Perù 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
AF - Afghanistan, Repubblica islamica di 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
CG - Congo 1
EE - Estonia 1
GA - Gabon 1
GN - Guinea 1
GR - Grecia 1
GT - Guatemala 1
HT - Haiti 1
HU - Ungheria 1
KG - Kirghizistan 1
KW - Kuwait 1
LC - Santa Lucia 1
LV - Lettonia 1
MD - Moldavia 1
MQ - Martinica 1
MR - Mauritania 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
PG - Papua Nuova Guinea 1
QA - Qatar 1
RO - Romania 1
Totale 7.211
Salva come PNG Salva come JPEG
Città #
Singapore 690
Hefei 386
San Jose 340
Moscow 228
Santa Clara 167
Hong Kong 166
Ashburn 163
Ho Chi Minh City 127
Beijing 124
Munich 113
Krefeld 111
Hanoi 93
Seoul 83
Kochi 82
Chandler 74
Lauterbourg 55
Los Angeles 55
Helsinki 52
Tokyo 44
The Dalles 43
Bad Bellingen 42
New York 41
São Paulo 36
Dallas 30
Redondo Beach 28
Chicago 26
Buffalo 22
Da Nang 22
Boardman 19
Milan 18
Boston 17
Houston 17
Haiphong 15
Lappeenranta 14
Naples 14
Rome 14
Chennai 13
Frankfurt am Main 13
Rio de Janeiro 13
Warsaw 13
Biên Hòa 12
Seattle 12
London 11
Mexico City 11
Montreal 11
Orem 11
Atlanta 10
Brooklyn 10
Pune 10
Toronto 10
Falkenstein 9
Council Bluffs 7
Denver 7
Lahore 7
Phoenix 7
Porto Alegre 7
Rochdale 7
San Francisco 7
Xi'an 7
Amman 6
Belo Horizonte 6
Campinas 6
Dublin 6
Jyväskylä 6
Manchester 6
Nairobi 6
Poplar 6
Ribeirão Preto 6
Stockholm 6
Turku 6
Amsterdam 5
Bắc Giang 5
Calgary 5
Curitiba 5
Erbil 5
Guangzhou 5
Johannesburg 5
Karlsruhe 5
Kingston 5
Nuremberg 5
Campo Grande 4
Can Tho 4
Düsseldorf 4
Fortaleza 4
Guayaquil 4
Memphis 4
Paris 4
Phủ Lý 4
Quito 4
Salvador 4
Santo André 4
Turin 4
Washington 4
Zhengzhou 4
Ankara 3
Athens 3
Bad Durrheim 3
Baghdad 3
Baku 3
Basra 3
Totale 3.986
Salva come PNG Salva come JPEG
Nome #
Effect of Dupilumab on Sexual Desire in Adult Patients with Moderate to Severe Atopic Dermatitis 467
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study 398
Alopecia Areata after COVID-19 Vaccines 159
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 159
Management of Psoriasis Patients with Serious Infectious Diseases 152
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience 135
Real-world practice indirect comparison between guselkumab, risankizumab and tildrakizumab: results from an Italian 28-week retrospective study 135
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 133
Comment on ‘Anogenital dermatology: challenges in the digital era’ 132
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 129
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature 127
The impact of COVID ‐19 infection on psoriatic patients treated with biologics: an Italian experience 127
An uncommon case of lichen spinulosus induced by dupilumab in a patient treated for bronchial asthma 126
Treatment of hereditary hypotrichosis simplex of the scalp with oral minoxidil and growth factors 125
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature 123
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis 122
Leg paralysis after photodynamic therapy for Lymphomatoid Papulosis: a case report 122
Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real‐life study 120
COVID-19 and cutaneous manifestations: A review of the published literature 120
Risk Factors for Psoriasis Flares: A Narrative Review 119
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis 118
Hidradenitis Suppurativa Cancer Risk: A Review of the Literature 117
Acrodermatitis continua of Hallopeau successfully treated with ixekizumab: A case report 117
Generalized versus localized vitiligo after ixekizumab: May previous treatment affect the clinical presentation? 115
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19 113
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials 111
Epidermolysis bullosa: new insights for the future 110
Immune response to Covid‐19 mRNA vaccination in psoriasis patients undergoing treatment with biologics 110
A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab 107
Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a psoriasis patient. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab" 107
Reply to “Nail psoriasis: a rare mRNA COVID ‐19 vaccine reaction” by Lamberti A et al 106
Comment on ‘Pityriasis rubra pilaris-like eruption following mRNA COVID-19 vaccine’ 105
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 104
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? 103
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review 102
Pemphigus Vulgaris and COVID-19 vaccination: Management and Treatment 101
Guselkumab-induced vitiligo in a patient with psoriatic arthritis 100
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature 98
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." 98
Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study 98
Comment on 'Morphoea following COVID-19 vaccination' 96
Dupilumab for the treatment of adult atopic dermatitis in special populations 95
COVID-19 vaccination and inflammatory skin diseases 94
Atypical case of cutaneous Rosai-Dorfman disease 93
Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa' 92
Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review 89
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study 87
Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes—A Review of the Literature 85
Reply to ‘Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa’ by Holgersen et al 85
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report 82
Viral Reactivation Following COVID-19 Vaccination: a review of the current literature 80
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data 78
Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa” 72
Bullous pemphigoid and COVID ‐19 vaccination: management and treatment Reply to ‘Bullous pemphigoid in a young male after COVID ‐19 mRNA vaccine: a report and brief literature review’ by Pauluzzi et al 68
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report 66
Reply to “Dalbavancin for the treatment of severe hidradenitis suppurativa” 66
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study 65
Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association 63
Allergic contact dermatitis to petrolatum: An unknown for patch testing 62
Advancing Dermatology: Embracing the Power of Artificial Intelligence 62
Comment on ‘Eosinophilic pustular folliculitis developing at the site of COVID-19 vaccination’ 62
Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments 59
Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient 53
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era? 53
Comment on ‘Onset of epidermolysis bullosa acquisita under therapy with ustekinumab for the treatment of Crohn disease’ 52
The impact of tildrakizumab on quality of life in patients suffering from moderate-to-severe psoriasis: a 36-week prospective, monocentric, real-life, observational study 52
Totale 7.281
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.448
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.448
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20229 0 0 0 0 0 0 0 1 0 1 2 5
2022/2023284 4 16 3 15 35 29 13 40 37 18 33 41
2023/2024657 11 41 49 22 13 28 10 50 316 16 60 41
2024/20252.199 77 92 15 12 85 171 221 176 150 263 789 148
2025/20263.895 414 645 424 426 565 158 333 223 355 181 88 83
2026/2027237 237 0 0 0 0 0 0 0 0 0 0 0
Totale 7.281